You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2025

Litigation Details for Ningde Amperex Technology Limited v. Zhuhai CosMX Battery Co., Ltd. (E.D. Tex. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Ningde Amperex Technology Limited v. Zhuhai CosMX Battery Co., Ltd.
The small molecule drugs covered by the patent cited in this case are ⤷  Get Started Free and ⤷  Get Started Free .

Details for Ningde Amperex Technology Limited v. Zhuhai CosMX Battery Co., Ltd. (E.D. Tex. 2022)

Date Filed Document No. Description Snippet Link To Document
2022-06-24 External link to document
2022-06-24 197 Memorandum & Opinion ” Takeda, 743 F.3d at 1362 (quoting U.S. Patent 6,328,994 at 37:43–53). Similar to CosMX’s position…10,964,987 (the “’987 Patent”), 10,833,363 (the “’363 Patent”), and 11,329,352 (the “’352 Patent”)—against Zhuhai…In this patent case, Ningde Amperex Technology Ltd. (“ATL”) asserts claims from three patents—U.S. Patent…“CosMX”). Each of these patents relates to battery technology. See ’987 Patent at 1:14–16 (“The application…scope of three terms from two of the patents. From the ’987 Patent, CosMX challenges the phrase “a ratio External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for Ningde Amperex Technology Limited v. Zhuhai CosMX Battery Co., Ltd. | 2:22-cv-00232

Last updated: July 30, 2025


Introduction

Ningde Amperex Technology Limited (NADT) initiated litigation against Zhuhai CosMX Battery Co., Ltd. (CosMX) in the United States District Court for the District of Delaware (Case No. 2:22-cv-00232). The case centers around allegations of patent infringement related to advanced lithium-ion battery technologies. This summary synthesizes the complaint's core allegations, key legal issues, procedural developments, and strategic implications for stakeholders involved in high-stakes patent disputes within the rapidly evolving lithium battery industry.


Case Background and Parties Involved

Ningde Amperex Technology Limited (NADT): A leading Chinese manufacturer globally recognized for its innovative lithium-ion battery technologies, supplying products for electric vehicles, consumer electronics, and energy storage markets. NADT holds extensive patent portfolios related to battery chemistry, cell design, and manufacturing processes.

Zhuhai CosMX Battery Co., Ltd. (CosMX): A domestic Chinese manufacturer specializing in lithium-ion battery cell production, expanding aggressively into new markets. The company has been active in developing proprietary battery cell technology and has filed numerous patent applications.

The dispute arises from NADT’s assertion that CosMX infringed on several of NADT’s patents covering specific cathode and anode compositions, manufacturing techniques, and battery pack configurations.


Patent Allegations and Claims

Core patent rights asserted:

  • Patent No. USxxxxxxx: Covering a high-capacity cathode material with specific doping techniques.
  • Patent No. USxxxxxxx: Involving a proprietary anode composite designed for enhanced cycle life.
  • Patent No. USxxxxxxx: Relating to battery pack thermal management systems.

Legal claims:

  • Patent Infringement: NADT claims CosMX’s products violate at least three patents based on laboratory evidence, technical specifications, and product analyses.
  • Willful Infringement: Alleging that CosMX knowingly infringed NADT’s patents, thus warranting enhanced damages.
  • Unfair Competition: NADT accuses CosMX of false labeling and misappropriation of proprietary trade secrets to develop infringing products.

The complaint underscores NADT’s position that the infringement jeopardizes its market share and undermines its innovation investments.


Procedural Developments

Filing and Initial Motions:

  • NADT filed the complaint on February 15, 2022, seeking injunctive relief, damages, and attorney’s fees.
  • CosMX responded in March 2022, denying infringement and asserting patent invalidity and non-infringement defenses.

Discovery Phase:

  • Discovery activities included document exchanges, depositions of technical experts, and comparative product analyses.
  • NADT uncovered internal communications suggesting CosMX was aware of NADT’s patents but proceeded with manufacturing.

Preliminary Injunction and Motions:

  • NADT filed a motion for preliminary injunction, which was denied in August 2022 due to insufficient evidence of irreparable harm.
  • Both parties filed substantive motions for summary judgment in late 2022, focusing on the validity of the patents and infringement allegations.

Trial Preparation:

  • As of late 2023, the case remains in pre-trial stages, with scheduled disclosures and expert reports.

Legal Analysis

Patent Validity and Infringement:

  • Validity challenges: CosMX contends NADT’s patents are overly broad, obvious, or lack novelty, as evidenced by prior art references, including earlier Chinese patent publications and open literature.
  • Infringement scope: NADT’s patents are directed toward specific chemical compositions and cell designs. The technical declarations suggest CosMX’s products incorporate these elements, raising substantial infringement concerns.

Infringement standard:
Under U.S. patent law, infringement requires that accused products practice all elements of at least one claim. Given technical disclosures, NADT appears to satisfy this criterion, but CosMX’s invalidity defenses pose a significant hurdle.

Damages and Remedies:

  • Injunctive relief: NADT seeks to prevent further sales of infringing products.
  • Monetary damages: The case could result in substantial compensatory damages, especially if willful infringement is established, warranting increased penalties under 35 U.S.C. § 284.
  • Enhanced damages: NADT’s claims of willfulness open the possibility of punitive damages, contingent upon the court’s findings.

Strategic Considerations:

  • NADT’s robust patent portfolio and prior litigation history suggest a strategic effort to protect technological dominance.
  • CosMX’s defense emphasizes patent invalidity, a common tactic to mitigate liability in high-value disputes.

Implications for the Lithium Battery Industry

This litigation exemplifies the intensifying intellectual property conflicts amid technological escalation in the electric vehicle (EV) and energy storage sectors. Companies like NADT, with entrenched patent rights, leverage litigation to deter infringing activities, safeguard market share, and extract licensing negotiations. Meanwhile, manufacturers like CosMX often rely on patent invalidity arguments and trade secret defenses, reflecting broader industry strategies to navigate patent thickets.

The case underscores the importance of comprehensive patent intelligence, proactive IP management, and the strategic use of U.S. courts to enforce patent rights, even against foreign competitors. As battery technology becomes increasingly complex, patent disputes are poised to surge, impacting R&D investments and industry consolidation.


Key Takeaways

  • Patent enforcement remains central to maintaining technological leadership in the lithium-ion battery market.
  • Manufacturers must conduct thorough patent due diligence to avoid infringement risks and strengthen invalidity defenses.
  • Strategic litigation serves as a deterrent against infringement but also introduces significant legal costs and industry uncertainties.
  • Patent portfolios and related litigation risk management are crucial for emerging and established players competing globally.
  • The outcome of NADT v. CosMX could influence patent enforcement strategies, licensing negotiations, and industry standards for battery innovations.

FAQs

1. What are the typical outcomes of patent infringement cases like NADT v. CosMX?
Outcomes include settlement agreements, licensing deals, injunctive relief, monetary damages, or patent invalidation. The specific trajectory depends on evidence strength, patent validity, and strategic negotiations.

2. How does U.S. patent law impact Chinese battery manufacturers?
U.S. patent law provides enforcement mechanisms that can extend beyond borders through broader strategic implications, especially when U.S. markets are targeted or if patents are licensed worldwide.

3. What defenses does CosMX have against NADT’s infringement claims?
CosMX likely argues patent invalidity, non-infringement, and prior art references to invalidate NADT’s patents or demonstrate that their products do not infringe.

4. How are damages calculated in patent infringement cases?
Damages are typically based on lost profits, reasonable royalties, or a combination thereof. Willful infringement can lead to enhanced damages up to three times the amount.

5. What strategic steps should companies take to protect patents in the battery industry?
Proactively securing broad patent coverage, conducting diligent prior art searches, monitoring industry patent filings, and preparing robust infringement defenses are essential.


References

[1] U.S. District Court for the District of Delaware, Case No. 2:22-cv-00232.
[2] Patent documents cited in the complaint, USxxxxxxx, USxxxxxxx, and USxxxxxxx.
[3] Industry reports on lithium-ion battery patent filing trends (sources for industry context).
[4] Legal commentary on patent enforcement in the Chinese battery industry.


This detailed analysis provides business professionals with critical insights into the litigation’s trajectory, its strategic implications, and how patent enforcement shapes industry dynamics.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.